ReviewPediatric pulmonology2026
The Value of Nasal Nitric Oxide Measurement in the Diagnosis of Primary Ciliary Dyskinesia.
Review in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal nitric oxide (nNO) is widely used as a first-line test in the diagnostic evaluation of primary ciliary dyskinesia (PCD). Although low nNO is characteristic of classic PCD forms, its diagnostic performance varies across age groups, measurement techniques, and genetic subtypes. This review summarizes current evidence on the diagnostic accuracy of nNO and its evolving position within PCD guidelines. In recent prospective referral cohorts using comprehensive diagnostic work-ups, pooled sensitivity and specificity remain high, though slightly lower than in earlier, more selected cohorts. Previous European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines took different positions on the role of nNO, but the newly published joint ERS-ATS guideline harmonizes these approaches and recommends nNO as an important, though not stand-alone, component of the diagnostic pathway. Growing recognition of PCD genotypes with preserved ultrastructure and relatively normal nNO values has broadened the clinical spectrum. In these individuals, as well as in patients classified as "probable PCD" (no genetic or electron microscopic confirmation), diagnostic performance is reduced, with greater overlap between PCD and non-PCD populations. Age-adjusted reference values improve discrimination but do not eliminate this overlap. Additional factors, including technique, cooperation, ambient NO, and infection status, further influence interpretation. In conclusion, PCD represents a heterogeneous spectrum of motile ciliopathies with substantial variation in ultrastructure, ciliary function, symptoms, and nNO. Given this heterogeneity, no single biomarker can be expected to perform uniformly across all subtypes. nNO should therefore be interpreted in conjunction with clinical features and complementary diagnostic tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.